RE:RE:RE:RE:Pharma companies should be lining up to partner with us There is real money to be made and that will attract partnerships if they see potencial and revenues ..
The FDA said it will continue to monitor the drug as it reaches the U.S. market. The agency granted approval on the condition that Biogen conduct another clinical trial. The Massachusetts-based biotechnology company said Monday that aducanumab's list price is $56,000 per year; $4,312 per infusion.
retiredcop wrote: Maybe .lets allow everyone to digest what's actually happened with Biogen...the next few days we will see if the nay sayers have changed their outlook now that Biogen got approval with no real conditions on what stage ad suffers could access the treatment. This no cavetes approval actually surprised people in PMN..and I think there are a lot of really happy people at PMN, looking at how they can use this approval to our advantage .I would not expect a jv right away...potential partners need to monitor what they think the new ad drug will bring in for money...once that is established it becomes a lot more urgent to Get into the ad drug game....